Business
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade 2 IEC-HS which resolved) ○ Durability: in patients who achieved MRD-negative CR/CRi, median OS was 14.8 months ○ In the target Phase 2 population, CR/CRi rate of 56% with ~80% of patients achieving MRD-negative status ○ In the target Phase 2 population, 100% patients became transpl
About this update from Cellectis S.a.
[{"type":"image","alt":"Cellectis Inc.","displaySize":"","headline":null,"caption":"Cellectis Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":119,"url":"https://media.zenfs.com/en/globenewswire.com/f68f579f9ddafa91af53fffe1d842d97"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U3etrkPEbdAWocW4KkNDeA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f68f579f9ddafa91af53fffe1d842d97","width":300,"height":119}},"lazy":false},{"type":"text","content":"○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9)","length":122,"tagName":"p"},{"type":"text","content":"○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade 2 IEC-HS which resolved)","length":124,"tagName":"p"},{"type":"text","content":"○ Durability: in patients who achieved MRD-negative CR/CRi, median OS was 14.8 months","length":90,"tagName":"p"},{"type":"text","content":"○ In the target Phase 2 population, CR/CRi rate of 56% with ~80% of patients achieving MRD-negative status","length":106,"tagName":"p"},{"type":"text","content":"○ In the target Phase 2 population, 100% patients became transplant eligible with 78% proceeding to transplant","length":110,"tagName":"p"},{"type":"text","content":"○ Among 11 patients previously treated with all 3 targeted therapies (inotuzumab, blinatumomab, and CD19 CAR-T), 8 responded and 7 achieved MRD-negative status","length":159,"tagName":"p"},{"type":"text","content":"○ BALLI-01 pivotal Phase 2 in r/r B-ALL initiated","length":49,"tagName":"p"},{"type":"text","content":"○ Potential peak gross sales of up to ~$700 million across the U.S., EU4, UK","length":76,"tagName":"p"},{"type":"text","content":"NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today hosted an R&D Day providing promising clinical data from the Phase 1 BALLI-01 study of lasme-cel (UCART22) for transplant ineligible patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in the third line or beyond (3L+). The Company unveiled the design of the pivotal Phase 2, its planned ...